Cargando…

Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL

PURPOSE: To facilitate the measurement of quality of life in sarcopenia, we set out to reduce the number of items in the previously validated Sarcopenia Quality of Life (SarQoL(®)) questionnaire, and to evaluate the clinimetric properties of this new short form. METHODS: The item reduction process w...

Descripción completa

Detalles Bibliográficos
Autores principales: Geerinck, A., Beaudart, C., Reginster, J.-Y., Locquet, M., Monseur, C., Gillain, S., Bruyère, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298237/
https://www.ncbi.nlm.nih.gov/pubmed/33782793
http://dx.doi.org/10.1007/s11136-021-02823-3
_version_ 1783726023128383488
author Geerinck, A.
Beaudart, C.
Reginster, J.-Y.
Locquet, M.
Monseur, C.
Gillain, S.
Bruyère, O.
author_facet Geerinck, A.
Beaudart, C.
Reginster, J.-Y.
Locquet, M.
Monseur, C.
Gillain, S.
Bruyère, O.
author_sort Geerinck, A.
collection PubMed
description PURPOSE: To facilitate the measurement of quality of life in sarcopenia, we set out to reduce the number of items in the previously validated Sarcopenia Quality of Life (SarQoL(®)) questionnaire, and to evaluate the clinimetric properties of this new short form. METHODS: The item reduction process was carried out in two phases. First, information was gathered through item-impact scores from older people (n = 1950), a Delphi method with sarcopenia experts, and previously published clinimetric data. In the second phase, this information was presented to an expert panel that decided which of the items to include in the short form. The newly created SFSarQoL was then administered to older, community-dwelling participants who previously participated in the SarcoPhAge study. We examined discriminative power, internal consistency, construct validity, test–retest reliability, structural validity and examined item parameters with a graded response model (IRT). RESULTS: The questionnaire was reduced from 55 to 14 items, a 75% reduction. A total of 214 older, community-dwelling people were recruited for the validation study. The clinimetric evaluation showed that the SF-SarQoL(®) can discriminate on sarcopenia status [EWGSOP2 criteria; 34.52 (18.59–43.45) vs. 42.86 (26.56–63.69); p = 0.043], is internally consistent (α = 0.915, ω = 0.917) and reliable [ICC = 0.912 (0.847–0.942)]. A unidimensional model was fitted (CFI = 0.978; TLI = 0.975; RMSEA = 0.108, 90% CI 0.094–0.123; SRMR = 0.055) with no misfitting items and good response category separation. CONCLUSIONS: A new, 14-item, short form version of the Sarcopenia Quality of Life questionnaire has been developed and shows good clinimetric properties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-021-02823-3.
format Online
Article
Text
id pubmed-8298237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-82982372021-07-23 Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL Geerinck, A. Beaudart, C. Reginster, J.-Y. Locquet, M. Monseur, C. Gillain, S. Bruyère, O. Qual Life Res Article PURPOSE: To facilitate the measurement of quality of life in sarcopenia, we set out to reduce the number of items in the previously validated Sarcopenia Quality of Life (SarQoL(®)) questionnaire, and to evaluate the clinimetric properties of this new short form. METHODS: The item reduction process was carried out in two phases. First, information was gathered through item-impact scores from older people (n = 1950), a Delphi method with sarcopenia experts, and previously published clinimetric data. In the second phase, this information was presented to an expert panel that decided which of the items to include in the short form. The newly created SFSarQoL was then administered to older, community-dwelling participants who previously participated in the SarcoPhAge study. We examined discriminative power, internal consistency, construct validity, test–retest reliability, structural validity and examined item parameters with a graded response model (IRT). RESULTS: The questionnaire was reduced from 55 to 14 items, a 75% reduction. A total of 214 older, community-dwelling people were recruited for the validation study. The clinimetric evaluation showed that the SF-SarQoL(®) can discriminate on sarcopenia status [EWGSOP2 criteria; 34.52 (18.59–43.45) vs. 42.86 (26.56–63.69); p = 0.043], is internally consistent (α = 0.915, ω = 0.917) and reliable [ICC = 0.912 (0.847–0.942)]. A unidimensional model was fitted (CFI = 0.978; TLI = 0.975; RMSEA = 0.108, 90% CI 0.094–0.123; SRMR = 0.055) with no misfitting items and good response category separation. CONCLUSIONS: A new, 14-item, short form version of the Sarcopenia Quality of Life questionnaire has been developed and shows good clinimetric properties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-021-02823-3. Springer International Publishing 2021-03-30 2021 /pmc/articles/PMC8298237/ /pubmed/33782793 http://dx.doi.org/10.1007/s11136-021-02823-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Geerinck, A.
Beaudart, C.
Reginster, J.-Y.
Locquet, M.
Monseur, C.
Gillain, S.
Bruyère, O.
Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title_full Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title_fullStr Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title_full_unstemmed Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title_short Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL
title_sort development and validation of a short version of the sarcopenia quality of life questionnaire: the sf-sarqol
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298237/
https://www.ncbi.nlm.nih.gov/pubmed/33782793
http://dx.doi.org/10.1007/s11136-021-02823-3
work_keys_str_mv AT geerincka developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT beaudartc developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT reginsterjy developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT locquetm developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT monseurc developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT gillains developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol
AT bruyereo developmentandvalidationofashortversionofthesarcopeniaqualityoflifequestionnairethesfsarqol